443 results
Other coronary interventions: SSO2, angioPy & more
16 May 2024 – From EuroPCR 2024
This session showcases a diverse array of innovative coronary interventions and technologies, including the use of super-saturated oxygen therapy in STEMI, the validation of intracoronary flow velocity measurement, the application of laser and optics-based coronary intravascular lithotripsy, and the development of contrast-free and X-ray-free PCI techniques....
Physiology guided post-DCB treatment to safely limit stenting. Validation in complex clinical settings with the optical Optowire III pressure guidewire
16 May 2024 – From EuroPCR 2024
Follow this session to discover how accurate resting index can inform decision-making for DCB in CTO patients and understand the role of physiology in a new PCI workflow for complex MVD. Thus, you will learn about a DCB intention-to-treat strategy guided by post-PCI coronary physiology in...
REC-CAGEFREE II, NOTION-2, LANDMARK: Three major late-breaking trials presented at EuroPCR 2024
15 May 2024
The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice.
Randomised trials: substudies and extended follow-up - A quick update
15 May 2024 – From EuroPCR 2024
This session provides a quick update on various randomised trials, including substudies and extended follow-up data. It covers insights on bifurcation stenting, the symptom-stratified analysis of ORBITA-2, the impact of completeness of revascularisation on clinical outcomes from REVIVED-BCIS2, cost-effectiveness of CABG vs. PCI from FAME 3,...
The ARC consensus on DCB - evidence-based DCB technology
15 May 2024 – From EuroPCR 2024
In this replay, discover why DCBs are essential in treating de novo CAD, the importance of optimal lesion preparation for long-term success, and how future trials will focus on treatment strategies rather than device comparisons, highlighting the need for further research.
Artificial intelligence-powered quantification of coronary physiology and vulnerable plaque: opportunities for novel treatment options
15 May 2024 – From EuroPCR 2024
In this session, uncover new data on Murray-law based quantitative flow ratio (muFR) assessment, providing a comprehensive understanding of PCI outcomes from a single angiographic view, explore the innovative application of artificial intelligence in identifying vulnerable plaque and assessing hemodynamic stenosis significance through the analysis of...
Complex PCI in ACS patient with high bleeding risk: optimise the strategy
15 May 2024 – From EuroPCR 2024
Watch this session for insights into managing acute coronary syndrome patients with multivessel disease, updates on treatment approaches, comparing FULL RESVAC with previous trials like COMPLETE or FIRE, for example, and information on ongoing trials such as FRAMI-AMI 2 and 3. Explore the LIVE case presentation...
Second generation biolimus drug-coated balloon in clinical practice
15 May 2024 – From EuroPCR 2024
Discover the potential applications of the new biolimus-coated balloon in treating de novo large vessel lesions, explore its effectiveness in addressing ISR based on findings from the BIO ASCEND ISR study, and uncover insights into the safety and feasibility of BA9 DCB in treating small vessel,...
Go beyond metal: exploring drug-eluting balloon technology in de-novo coronary lesions
15 May 2024 – From EuroPCR 2024
Through the study of two cases, this session examines the need for stenting bifurcation lesions and the role of DEB technology in avoiding stent-related complications in long diffuse disease. It emphasizes the benefits of SELUTION SLR balloons for de novo lesions, discussing how sustained limus release...
Tools and technologies guiding decision making in bifurcation PCI
15 May 2024 – From EuroPCR 2024
In this session, discover that provisional stenting in routine non-LM bifurcation using Resolute Onyx DES yields good mid-term outcomes without side branch intervention, provided the stent is sized to the distal reference and the side branch remains patent after a systematic POT. Learn how bifurcation stenting...
